Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. ("TG" or the "Company") Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether TG and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On September 25, 2018, TG announced that it would not be releasing data from the UNITY-CLL Phase 3 study of the Company's leukemia treatment TG-1101 (ublituximab) and that the study had failed to meet the overall response rate ("ORR") stated goal. In a press release, TG announced that the trial's Data Safety Monitoring Board had met to review ongoing data from the UNITY-CLL study and advised the Company that the interim analysis of the ORR could not be conducted at that time because the data was not sufficiently mature to conduct the analysis.
Following this news, TG's stock price fell $4.10 per share, or 44.32%, to close at $5.15 per share on September 25, 2018.